Breaking News Instant updates and real-time market news.

VRX

Valeant

$22.24

-0.53 (-2.33%)

12:55
10/14/16
10/14
12:55
10/14/16
12:55

Valeant announces price raises of 2%-9% in certain portfolios

Valeant Pharmaceuticals announced that the company's Patient Access and Pricing Committee has made decisions regarding price changes of products in the company's neurology, GI and urology portfolios. The planned wholesale acquisition price changes, effective October 14, range from 2% to 9%. "The changes are aligned with the Committee's commitment that the average annual price increase for Valeant's prescription pharmaceutical products will be set at no greater than single digits and below the 5-year weighted average of the increases within the branded biopharmaceutical industry," the company said in a statement. Valeant added that its 2016 pricing actions across its U.S. branded Rx portfolio, represent an increase of less than 2.0% within the calendar 2016 year. On a forward looking annualized basis, 2016 price actions are in line with 2016 Consumer Price Index of 2.3%, it explained. "In 2016, net pricing of Valeant's Dermatology and Ophthalmology products, after taking into account the impact of rebates and other adjustments, will have decreased by greater than 10% on average. There will be no pricing adjustments this year on Dermatology and Ophthalmology products," Valeant stated. Joseph Papa, Valeant CEO, said, "In reviewing product pricing, the Committee considers overall market dynamics along with the impact of any price increase on patients, doctors, and our health care industry partners. We believe the actions announced today are consistent with our commitment to ensure that patients continue to have access to the medicines they need at an affordable price and demonstrate that we are taking our approach to responsible pricing seriously."

  • 16

    Nov

  • 14

    Dec

VRX Valeant
$22.24

-0.53 (-2.33%)

09/19/16
WELS
09/19/16
NO CHANGE
WELS
Price increases could be negative sign, says Wells Fargo
After Valeant increased the list prices of three of its products with combined sales of $1.2M last year, Wells Fargo says further price increases could be forthcoming, and the price increases could indicate that the company feels it needs to raise prices to meet its 2H16 guidance. Noting that the company raised the list price on each of the products by 9.9%, Wells believes that the company could have raised prices by that amount instead of 10% to "stay under the radar of managed care plans and states" looking to prevent double digit price increases. Wells keeps an Underperform rating on the stock.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.

TODAY'S FREE FLY STORIES

LBTYA

Liberty Global

$36.99

0.56 (1.54%)

06:11
02/27/17
02/27
06:11
02/27/17
06:11
Conference/Events
Liberty Global management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

AES

AES Corp.

$11.93

0.18 (1.53%)

06:10
02/27/17
02/27
06:10
02/27/17
06:10
Earnings
AES Corp. sees 8%-10% annual growth in EPS, cash flow through 2020 »

Expects 8% to 10% average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

AES

AES Corp.

$11.93

0.18 (1.53%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Earnings
AES Corp. reports Q4 adjusted EPS 35c, consensus 36c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

SHOO

Steven Madden

$37.15

-0.1 (-0.27%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Upgrade
Steven Madden rating change  »

Steven Madden upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SYT

Syngenta

$85.27

0.3 (0.35%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Periodicals
ChemChina's Syngenta bid seen receiving conditional EU approval, Reuters says »

The EU is set to give…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRX

BioCryst

$5.49

-0.11 (-1.96%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Hot Stocks
BioCryst reports 'positive' interim results from APeX-1 trial »

BioCryst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

06:07
02/27/17
02/27
06:07
02/27/17
06:07
Hot Stocks
Buffett says market 'not in bubble territory' or 'anything of the sort' »

Warren Buffett, while…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

, KR

Kroger

$33.29

0.3 (0.91%)

06:06
02/27/17
02/27
06:06
02/27/17
06:06
Periodicals
Wal-Mart launching price-comparison test in U.S., targeting Aldi, Reuters says »

Wal-Mart (WMT) is…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

KR

Kroger

$33.29

0.3 (0.91%)

PG

Procter & Gamble

$91.05

-0.08 (-0.09%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

CAG

Conagra Brands

$41.16

0.66 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

LJPC

La Jolla

$19.87

1.65 (9.06%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Hot Stocks
La Jolla announces positive results from ATHOS-3 Phase 3 study of LJPC-501 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$45.61

1.36 (3.07%)

06:04
02/27/17
02/27
06:04
02/27/17
06:04
Downgrade
PSEG rating change  »

PSEG downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Hot Stocks
Breaking Hot Stocks news story on UCP, Inc. »

UCP, Inc. reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LAUR

Laureate Education

$13.24

0.06 (0.46%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:02
02/27/17
02/27
06:02
02/27/17
06:02
Earnings
UCP, Inc. reports Q4 EPS 89c with benefits, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNAP

Snap Inc.

06:01
02/27/17
02/27
06:01
02/27/17
06:01
Periodicals
Snap founders tightened grip following dispute with Lightspeed, NYT reports »

Early Snap investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

GRAM

Grana y Montero

$3.32

-1.77 (-34.77%)

06:00
02/27/17
02/27
06:00
02/27/17
06:00
Downgrade
Grana y Montero rating change  »

Grana y Montero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

05:59
02/27/17
02/27
05:59
02/27/17
05:59
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.66

0.13 (0.10%)

, EBAY

eBay

$34.06

0.46 (1.37%)

05:58
02/27/17
02/27
05:58
02/27/17
05:58
Periodicals
Tech firms plan to file brief in favor of transgender rights, Axios reports »

Leading tech companies…

AAPL

Apple

$136.66

0.13 (0.10%)

EBAY

eBay

$34.06

0.46 (1.37%)

IBM

IBM

$181.35

-0.3 (-0.17%)

MSFT

Microsoft

PYPL

PayPal

$43.07

0.54 (1.27%)

CRM

Salesforce

$81.78

-0.29 (-0.35%)

YELP

Yelp

$33.46

-0.01 (-0.03%)

BOX

Box

$17.93

0.41 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 09

    May

AFL

Aflac

$71.71

-0.01 (-0.01%)

05:57
02/27/17
02/27
05:57
02/27/17
05:57
Upgrade
Aflac rating change  »

Aflac upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

FTI

TechnipFMC

$32.30

-0.58 (-1.76%)

05:56
02/27/17
02/27
05:56
02/27/17
05:56
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$57.00

2.32 (4.24%)

, ISIL

Intersil

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$57.00

2.32 (4.24%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

ENB

Enbridge

$41.34

-0.37 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

NCMI

National CineMedia

$12.08

-0.35 (-2.82%)

05:53
02/27/17
02/27
05:53
02/27/17
05:53
Recommendations
National CineMedia analyst commentary  »

National CineMedia added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

HMSY

HMS Holdings

$18.83

0.13 (0.70%)

05:48
02/27/17
02/27
05:48
02/27/17
05:48
Downgrade
HMS Holdings rating change  »

HMS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.